View Item 

Show simple item record

UK-68,798, A Class III Antiarrhythmic Drug with Antifibrillatory Properties
dc.contributor.authorBlack, Shawn C.en_US
dc.contributor.authorLucchesi, Benedict Roberten_US
dc.date.accessioned2010-06-01T21:44:40Z
dc.date.available2010-06-01T21:44:40Z
dc.date.issued1992-06en_US
dc.identifier.citationBlack, Shawn C.; Lucchesi, Benedict R. (1992). "UK-68,798, A Class III Antiarrhythmic Drug with Antifibrillatory Properties." Cardiovascular Drug Reviews 10(2): 170-181. <http://hdl.handle.net/2027.42/74787>en_US
dc.identifier.issn0897-5957en_US
dc.identifier.issn1527-3466en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74787
dc.format.extent796615 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights1992 Neva Press, Branford, Connecticuten_US
dc.subject.otherArrhythmiaen_US
dc.subject.otherClass III Antiarrhythmicen_US
dc.subject.otherDelayed Rectifier Currenten_US
dc.subject.otherPotassium Channel Blockeren_US
dc.subject.otherSudden Cardiac Deathen_US
dc.subject.otherVentricular Fibrillationen_US
dc.subject.otherVentricular Tachycardiaen_US
dc.titleUK-68,798, A Class III Antiarrhythmic Drug with Antifibrillatory Propertiesen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, U.S.A.en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74787/1/j.1527-3466.1992.tb00244.x.pdf
dc.identifier.doi10.1111/j.1527-3466.1992.tb00244.xen_US
dc.identifier.sourceCardiovascular Drug Reviewsen_US
dc.identifier.citedreferenceBalser JR, Hondeghem LM, Rosen DM. Amiodarone reduces time-dependent Ik activation. Circulation 1987; 76 ( suppl IV ): 151.en_US
dc.identifier.citedreferenceBazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353 – 70.en_US
dc.identifier.citedreferenceBlack SC, Chi L, Mu D-X, Lucchesi BR. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent. J Pharmacol Exp Ther 1991; 258: 416 – 23.en_US
dc.identifier.citedreferenceBrugada P, Wellens HJJ. The role of triggered activity in clinical ventricular arrhythmias. In: Rosenbaum MB, Elizari MV, eds. Frontiers of Cardiac Electrophysiology. The Hague: Martinus Nijhoff, 1983: 195 – 216.en_US
dc.identifier.citedreferenceChi L, Mu D-X, Driscoll EM, Lucchesi BR. Antiarrhythmic and electrophysiologic actions of CK-3579 and sematilide in a conscious canine model of sudden coronary death. J Cardiovasc Pharmacol 1990; 16: 312 – 24.en_US
dc.identifier.citedreferenceColatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action: mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990; 82: 2235 – 42.en_US
dc.identifier.citedreferenceCross PE, Arrowsmith JE, Thomas GN, Gwilt M, Burges RA, Higgins JA. Selective class II agents 1. Bis(arylalkyl)amines. J Med Chem 1990; 33: 1151 – 5.en_US
dc.identifier.citedreferenceDalrymple HW, Butler P, Sutton MR, Dodd MG. Effects of UK-68,798, a novel class III antiarrhythmic agent, in conscious dogs. J Mol Cell Cardiol 1989; 21 ( suppl II ): S10.en_US
dc.identifier.citedreferenceDangman KH, Miura DS. Effects of therapeutic concentrations of procainamide on transmembrane action potentials of normal and infarct one Purkinje fibers and ventricular muscle cells. J Cardiovasc Pharmacol 1989; 13: 846 – 52.en_US
dc.identifier.citedreferenceFollmer CH, Colatsky T. Block of the delayed rectifier potassium current Ik by flecainide and E-4031 in cat ventricular myocytes. Circulation 1990; 82: 289 – 93.en_US
dc.identifier.citedreferenceGordon I, Kannel WTB. Premature mortality from coronary heart disease: Framingham study. JAMA 1971; 215: 1617 – 25.en_US
dc.identifier.citedreferenceGwilt M, Arrowsmith JE, Blackburn KJ, et al. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 1991; 256: 318 – 24.en_US
dc.identifier.citedreferenceGwilt M, Milne AA, Solca AM, King RC. UK-68,798, a potent and selective class III antiarrhythmic agent, reduced dispersion of repolarization in canine hearts in situ induced by rapid pacing. Br J Pharmacol 1990; 99: 15P.en_US
dc.identifier.citedreferenceGwilt M, Solca AM, Burges RA, Blackburn KJ, Higgins AJ. Antifibrillatory action and haemodynamic properties of UK-68,798, a new class III antiarrhythmic agent, in anaesthetized dogs. J Mol Cell Cardiol 1989; 21 ( suppl II ): S11.en_US
dc.identifier.citedreferenceHondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation 1990; 81: 686 – 90.en_US
dc.identifier.citedreferenceKim SG, Felder SD, Figura A, Johnston DR, Mercando AD, Fisher JD. The prognostic value of the changes in the mode of ventricular tachycardia induction noted during therapy with amiodarone and a class la antiarrhythmic agent. Am J Cardiol 1987; 59: 1314 – 8.en_US
dc.identifier.citedreferenceKnilans TK, Lathrop DA, Nanasi PP, Schwartz A, Varro A. Rate and concentration-dependent effects of UK-68,798, a potent new class III antiarrhythmic, on canine Purkinje fibre action potential duration. Br J Pharmacol 1991; 103: 1568 – 72.en_US
dc.identifier.citedreferenceLynch JJ, Heaney LA, Wallace AA, Gehret JR, Selnick HG, Stein B. Suppression of lethal ischemic ventricular arrhythmias by the class III agent E4031 in a canine model of previous myocardial infarction. J Cardiovasc Pharmacol 1990; 15: 764 – 75.en_US
dc.identifier.citedreferenceLynch JJ, Wilber DJ, Montgomery DG, Hsieh TM, Patterson E, Lucchesi BR. Antiarrhythmic and antifibrillatory actions of the levo- and dextro-rotary isomers of sotalol. J Cardiovasc Pharmacol 1984; 6: 1132 – 41.en_US
dc.identifier.citedreferenceLynch JJ, Wilber D, Montgomery DG, Hsieh TM, Patterson E, Lucchesi BR. Suppression of lethal ischemic ventricular arrhythmias by the class III agent E4031 in a canine model of previous myocardial infarction. J Mol Cell Cardiol 1989; 21 ( suppl II ): S154.en_US
dc.identifier.citedreferencePatterson E, Eller BT, Abrams GD, Vasiliades J, Lucchesi BR. Ventricular fibrillation in a conscious canine preparation of sudden coronary death. Prevention by short and long-term amiodarone administration. Circulation 1983; 68: 857 – 64.en_US
dc.identifier.citedreferencePatterson E, Gibson JK, Lucchesi BR. Postmyocardial infarction reentrant ventricular arrhythmias in conscious dogs: suppression by bretylium tosylate. J Pharmacol Exp Ther 1981; 216: 453 – 8.en_US
dc.identifier.citedreferencePatterson E, Holland K, Eller BT, Lucchesi BR. Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarction. A conscious canine model of sudden coronary death. Am J Cardiol 1982; 50: 1414 – 23.en_US
dc.identifier.citedreferencePlatou ES, Refsum H, Hotvedt R. Class III antiarrhythmic action linked with positive inotropy: antiarrhythmic, electrophysiological, and hemodynamic effects of the sea-anenome polypeptide ATX II in the dog heart in situ. J Cardiovasc Pharmacol 1986; 8: 459 – 65.en_US
dc.identifier.citedreferenceRahimtoola SH, Zipes DP, Akhtar M, et al. Consensus statement of the conference on the state of the art of electrophysiologic testing in the diagnosis and treatment of patients with cardiac arrhythmias. Circulation 1987; 75 ( suppl III ): III3 – 7.en_US
dc.identifier.citedreferenceRichards DAB, Byth K, Ross DL, Uther JB. What is the best predictor of spontaneous ventricular tachycardia and sudden death after myocardial infarction. Circulation 1991; 83: 756 – 63.en_US
dc.identifier.citedreferenceRoden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Circ Res 1985; 56: 857 – 67.en_US
dc.identifier.citedreferenceSedgwick M, Rasmussen HS, Walker D, Cobbe SM. Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class HI antiarrhythmic drug. Br J Clin Pharmacol 1991; 31: 515 – 9.en_US
dc.identifier.citedreferenceSingh BN, Vaughan-Williams EM. The effect of amiodarone, a new anti-anginal drug on cardiac muscle. Br J Pharmacol 1970; 39: 657 – 67.en_US
dc.identifier.citedreferenceStrauss HC, Bigger JT, Hoffman BF. Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ Res 1970; 26: 661 – 78.en_US
dc.identifier.citedreferenceTande PM, BjØrnstad H, Yang T, Refsum H. Rate-dependent class III antiarrhythmic action, negative chronotropy, and positive inotropy of a novel Ik blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990; 16: 401 – 10.en_US
dc.identifier.citedreference32. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 312: 406 – 12.en_US
dc.identifier.citedreferenceVaughan-Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 17: 129 – 47.en_US
dc.identifier.citedreferenceWalker DK, Aherne GW, Arrowsmith JE, et al. Measurement of the class III antidysrhythmic drug, UK-68,798, in plasma by radioimmunoassay. J Pharm Biomed Anal 1991; 2: 141 – 9.en_US
dc.identifier.citedreferenceWilber DJ, Lynch JJ, Montgomery DG, Lucchesi BR. Postinfarction sudden death. Significance of inducible ventricular tachycardia and infarct size in a conscious canine model. Am Heart J 1985; 109: 8 – 18.en_US
dc.identifier.citedreferenceYang T, Tande PM, Refsum H. Negative chronotropic effect of a novel class III antiarrhythmic drug, UK-68,798, devoid of Β-blocking action on isolated guinea-pig atria. Br J Pharmacol 1991; 103: 1417 – 20.en_US
dc.identifier.citedreferenceZuanetti G, Corr PB. Antiarrhythmic efficacy of a new class III agent, UK-68,698, during chronic myocardial infarction: evaluation using three-dimensional mapping. J Pharmacol Exp Ther 1991; 256: 325 – 34.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1527-3466.1992.tb00244.x.pdf
Size:
777.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.